Product Details:
|
|
Place of Origin: | Xi'an ,China |
---|---|
Brand Name: | Wango |
Model Number: | WG-0031 |
Payment & Shipping Terms:
|
|
Minimum Order Quantity: | 10gram every time |
Price: | can be negotiable freely . |
Packaging Details: | 1mg,1g,10g small bottle ,1kg with double plastic container inside/Aluminum foil bag .Or as your request. |
Delivery Time: | 3-5 working days |
Payment Terms: | Western Union, L/C, T/T, MoneyGram |
Supply Ability: | 10kilogram 0ne month |
Detail Information |
|||
Appearence: | White Crystal Powder | Other Name: | Chiglitazar |
---|---|---|---|
Packing: | 1mg,1g,10g Small Bottle | Function: | Antidiabetic Treatments |
Highlight: | Sodium API Active Pharmaceutical,Antidiabetic Function API Active Pharmaceutical,WG 0031 Active Pharmaceutical Ingredient |
Product Description
Chiglitazar Sodium is a new molecular entity developed by Wanggo Biotechnology Co., LTD. It is a peroxisome proliferator activated receptor (PPAR) complete agonist that can simultaneously activate three subtypes of PPAR receptors (α, γ and δ). Chiglitazar Sodium is a Chinese chemical drug class. Approved for marketing by NMPA on October 19, 2021, single drug is suitable for improving glycemic control in adult patients with type 2 diabetes in combination with diet control and exercise .
Type 2 diabetes, formerly known as non-insulin-dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic metabolic disease, mostly occurring after the age of 35 to 40, and the incidence is increasing. The common symptoms are polyuria, polydipsia, polyophagia and weight loss. The main causes of type 2 diabetes include heredity, environment and lifestyle . The striking pathophysiological features are a reduction in insulin's ability to regulate glucose metabolism (insulin resistance) and a reduction in insulin secretion (relative reduction) due to impaired islet beta cell function. The prevalence of diabetes in China is mainly type 2 diabetes, accounting for more than 90% of the diabetes population, type 1 diabetes and other types of diabetes are rare. The incidence of diabetes is higher in males than in females, and in urban areas than in rural areas. The proportion of undiagnosed diabetes is higher, and the prevalence of diabetes in obese and overweight people increases significantly .
The approval of Chiglitazar Sodium is based on the results of two phase III trials of 525 patients with type 2 diabetes using placebo and 740 patients using sitagliptin, respectively. Sitagliptin significantly reduced HbA1c levels at 24 weeks, by 1.52% at 52 weeks. In terms of secondary efficacy measures, sitaglitastatin showed a long-term and sustained reduction in fasting glucose and 2 h postprandial glucose, with no secondary failure observed at 52 weeks. Two experiments of Chinese and western of sodium Glenn he showed significant hypoglycemic effect and good security for a long time, west Glenn he sodium in improving the insulin resistance, protection of beta islet cell function and regulate blood fat also shows a good potential of comprehensive prevention and treatment of type 2 diabetes mellitus and complications, can provide patients with better treatment effect, safety, Significantly improved the quality of life of patients .
FAQ
Enter Your Message